Cancer, Carcinoma, Tumors
Conditions
Keywords
solid tumors, solid malignancies
Brief summary
The primary purpose of this study is to evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies
Interventions
DRUGAZD4877
10 mg IV (3 weeks treatment 1 week rest)
Sponsors
AstraZeneca
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with solid tumour but which have no standard treatment or did not respond to previous treatments. * Patients who usually have mild symptoms capable of walking and light and sedentary work. * Patients who can stay in hospital at least during 4 weeks.
Exclusion criteria
* Patients who have received treatment with anti-cancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin. * Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function. * Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies | weekly |
Secondary
| Measure | Time frame |
|---|---|
| To determine the PK profile of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies | weekly |
Countries
Japan
Outcome results
None listed